Navigation Links
Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Date:4/26/2012

Royalty income decreased as lower royalties from 3TC, ZEFFIX and other products more than offset higher royalty income from ADDERALL XR and FOSRENOL.

Royalty income from 3TC and ZEFFIX continues to be adversely impacted by increased competition from other products. Also, since Q2 2011 Shire has not recognized royalty income for 3TC and ZEFFIX for certain territories due to a disagreement between GlaxoSmithKline ("GSK") and Shire about how the relevant royalty rates should be applied given the expiry dates of certain patents. GSK and Shire are holding discussions in order to seek to resolve the disagreement.

3.    Financial details

Cost of product sales

% of % of product product Q1 2012 sales Q1 2011 sales $M $M Cost of product sales (US GAAP) 158.4 14% 124.5 14% Transfer of manufacturing from Owings Mills - (2.8) Depreciation (7.2) (5.5) Cost of product sales (Non GAAP) 151.2 14% 116.2 13%

Non GAAP cost of product sales as a percentage of product sales increased due to slight dilution from DERMAGRAFT following the acquisition of ABH in Q2 2011.

R&D

% of % of product product Q1 2012 sales Q1 2011 sales $M $M R&D (US GAAP) 220.3 20% 177.9 20% Payments in respect of in-licensed and acquired products (23.0) - Depreciation (6.4) (4.7) R&D (Non GAAP) 190.9 17% 173.2 19%

Non GAAP R&D increased by $17.7 million, or 10%, due to increased investment in a number of targeted R&D programs, including new uses for VYVANSE, HGT 2310 for the treatment of Hunter Syndrome with CNS symptoms, as well as our other development programs. Non GAAP R&D in Q1 2012 also included ABH's R&D expenditure ($3.0 million) which was not incurred by Shire in Q1 2011.

US GAAP R&D increased by $42.4 million, or 24% over Q1 2011 as the up-front payments made to Sangamo and on acquisition of the US rights for prucalopride (marketed in certain countries in Europe as RESOLO
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... Market by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture ... Users (Hospitals), Advanced technologies - Global Forecast to ... is poised to reach $19,786.3 Million by 2019 ... of 6.8% from 2014 to 2019. ...
(Date:9/19/2014)... RESEARCH TRIANGLE PARK, N.C. , Sept. 19, ... company focused on cloud-based drug design and development, ... strategy. The company,s mission is to design new ... Phase 1 and 2 partners to further their ... enhance its portfolio investments. To support this business ...
(Date:9/19/2014)... 2014  4WEB Medical announces the formal launch of ... osteotomy implants on the market today at this ... in Chicago .  The Osteotomy Truss ... needs with 74 size options included in one versatile ... only 15 to 18 implant sizes, which limited a ...
Breaking Medicine Technology:Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 24WEB Medical Unveils 3D-Printed Osteotomy Truss System 2
(Date:9/19/2014)... Recent two-generation approaches to reducing poverty that help ... from researchers, advocates, and foundations. By combining education ... move to jobs that offer a path out ... for children, these programs aim to improve the ... a new report from the National Center for ...
(Date:9/19/2014)... at Jacksonville,s campus of Mayo Clinic have discovered a ... to both overproduction of toxic protein in the brains ... loss of communication between neurons both significant contributors ... the online issue of Neuron , ... drugs "may rejuvenate or rescue this pathway," says the ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Famous Vancouver ... announced that it has now become a one-stop-solution for ... and businesses in Vancouver. The company has achieved this ... services to its customers. While there are many companies ... to have a single vendor who can offer all ...
(Date:9/19/2014)... (PRWEB) September 20, 2014 As summer vacations ... DMD in Queens, NY now reminds area patients about the ... 80% of our population affected by gum disease, there is ... , For over 20 years Dr. Krishnan has treated patients ... office location. “Most patients that come in due to common ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- When it comes ... in the United States, while the District of Columbia ... the past decade, deaths from gun-related violence -- including ... the United States, the study revealed. Hawaii,s rate was ... of the spectrum, the District of Columbia had the ...
Breaking Medicine News(10 mins):Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:Pro Ace Now Provides Heating, Air Conditioning, Plumbing & Electrical Services under One Roof 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:U.S. Gun Deaths Lowest in Hawaii, Highest in D.C. 2
... , , ... ANDS ) announced that it has entered into ... in gross proceeds in a "registered direct" offering through the ... estimates that net proceeds from the offering will be approximately ...
... , Supermarket Gains Latest Pharmacy Management Technology, Will Offer Patients ... Boise, Idaho-based Albertson,s, LLC has selected PDX and affiliates ... its pharmacy technology solution. , , Albertson,s, LLC ... Enterprise Pharmacy System (EPS), unparalleled in efficiency, ...
... vascular congestion is an important mediator in heart failure, ... Journal of Cardiac Failure ( http://www.onlinejcf.com/ ), ... that venous endothelium is a key regulator of central ... (HF). The present study demonstrates that in venous ...
... 4 Fora Care announces the launch of their ... their Point of Care Testing (POCT) System at the ... June 6-8 at the Ernest N. Morial Convention Center, ... patients to safely and securely upload critical blood glucose ...
... LONDON, June 4 The latest issue of ... authoritative,review on sulfonylureas by Professor Ian Campbell, a leading ... Professor Campbell,s review focuses on sulfonylurea-induced hypoglycemia,(SIH), which is ... 2 diabetes. In the review he discusses the incidence ...
... , SAN FRANCISCO, June 4 Medivation, Inc. (Nasdaq: ... and chief executive officer, will present at the 8th Annual ... a.m. Eastern Time at the New York Palace Hotel. , ... and its clinical development programs for Dimebon for Alzheimer,s and ...
Cached Medicine News:Health News:Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering 2Health News:Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering 3Health News:Albertson's, LLC Selects PDX-NHIN-Rx.com to Provide Complete Pharmacy Management Solution 2Health News:Fora Care Inc. to Launch Cost-Effective Solution for Diabetes Care at ADA 69th Scientific Sessions 2Health News:Comprehensive Review on Sulfonylureas in the Latest Issue of Diabetic Hypoglycemia (05 June 2009) 2Health News:Medivation to Present at 8th Annual Needham Life Sciences Conference 2
MONOJECT Red/Yellow Mottled Stopper...
... BD Vacutainer® SST™ Tubes ... a polymer gel for ... used for serum determinations ... provide an efficient means ...
BD Vacutainer® Specialty Tubes - Sedimentation Rate Determination (SRD)...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: